BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » Page 168

BioInformant iPS Cell Data Featured on Centre for Commercialization of Regenerative Medicine

By Leave a Comment

BioInformant is excited to share that our induced pluripotent stem cell industry analytics have been featured on the “Signals Blog,” published by the Centre for Commercialization of Regenerative Medicine (CCRM). CCRM is a Canadian, not-for-profit organization supporting the development of foundational technologies that accelerate the commercialization of stem cell- and biomaterials-based products and therapies.

iPSC Infograhpics Featured on Centre for Commercialization of Regenerative Medicine CCRMThe post, titled Right Turn: Commercializing iPSCs – Infographics, states:  “The beauty of an infographic (or two) is it speaks for itself.”

Induced Pluripotent Stem Cells Infographics

View Full CCRM Post → 

 

(My Story) President of a Stem Cell Market Research Firm and a Stem Cell Patient

By 1 Comment

For the past 15 years, I have studied stem cells, including technology and research advances, as well as market trends. I have been fascinated with them for most of my adult life, founding BioInformant as the first and only market research firm to specialize in the stem cell industry.

As a result of this decision, I have had the honor of serving thousands clients from across the stem cell industry and been interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine.

However, it was only recently that I experienced the power of stem cells to impact my own life and health.

[Read more…]

“We’re not made of drugs, we’re made of cells”

By Leave a Comment

Below is a short and simple quote that we say often here at BioInformant…

Stem Cell Quote 2

Remember as you make medical decisions in your life that you are not made of drugs, you are made of cells. The source of every cell in your adult body was originally a stem cell.

The importance of stem cells to you and your capacity to a live longer and healthier life cannot be understated.
[Read more…]

BioInformant Releases Global Induced Pluripotent Stem Cell (iPSC) Industry Report

By Leave a Comment

The iPSC industry is rapidly expanding, following the first iPSC trial in humans, creation of the world’s largest iPSC biobank, major funding awards, a historic challenge to the “Yamanaka Patent”, a Supreme Court ruling affecting industry patent rights, and the announcement of an iPSC cellular therapy clinic scheduled to open in 2019. With iPSC patent dominance continuing to cluster in specific geographic regions, clinical trial and scientific publication trends are giving clear indicators of what may happen in the industry in 2015 and beyond.

iPSC Report Applications

This global strategic report is produced for:

  • Management of Stem Cell Product Companies
  • Management of Stem Cell Therapy Companies
  • Stem Cell Industry Investors

[Read more…]

Technical Attributes You Need to Know Invest in the Induced Pluripotent Stem Cell (iPSC) Market

By Leave a Comment

If you are an investor considering an opportunity related to induced pluripotent stem cells (iPSCs), the market can initially appear technical and confusing. However, if you focus on a few key points of understanding, you’ll be able to assess the technical attributes that matter, including what defines the cell type, advantages and disadvantages, key events driving market growth, and opportunities for commercialization.

To begin, the best place to start is with a clear definition of the cell type.

Definition of Induced Pluripotent Stem Cells

Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell artificially derived from a non-pluripotent cell – typically an adult somatic cell, by inducing a ‘forced’ expression of specific gene. [Read more…]

BioInformant's World-Class Clients